Preface | p. vii |
Contributors | p. xiii |
Evaluation of Risk | |
Overview of Clinical Risk Assessment | p. 3 |
Familial and Genetic Risk | p. 26 |
Endocrine Risk Factors | p. 43 |
Benign Breast Disease and Breast Cancer Risk | p. 57 |
Lifestyle, Environmental Factors, and Breast Cancer Risk | p. 70 |
Breast Cancer Risk in the Context of Overall Health | p. 80 |
Risk Management Strategies | |
Surveillance | |
Outcome of Routine Surveillance of the High-Risk Woman | p. 103 |
Newer Imaging Approaches to the High-Risk Woman | p. 116 |
Role of Breast Epithelial Sampling Techniques in High-Risk Women | p. 138 |
Chemoprevention | |
Biologic Basis for Breast Cancer Risk Reduction with Pharmacologic Agents | p. 159 |
Tamoxifen for Chemoprevention | p. 175 |
SERMs Other Than Tamoxifen for Chemoprevention | p. 186 |
Aromatase Inhibitors for Chemoprevention | p. 199 |
Quality of Life Issues with Endocrine Chemoprevention | p. 214 |
Improving Quality of Life for Women at High Risk for Breast Cancer: Symptom Management without Estrogen | p. 227 |
Surgical Prevention | |
Prophylactic Mastectomy and Oophorectomy | p. 241 |
Breast Reconstruction | p. 259 |
Practical Management Guidelines | |
Practical Management Guidelines | p. 289 |
Index | p. 294 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.